Abstract:Complications from diabetic retinopathy such as diabetic macular edema (DME) and proliferative diabetic retinopathy (PDR) constitute leading causes of preventable vision loss in working-age patients. Since vascular endothelial growth factor (VEGF) plays a major role in the pathogenesis of these complications, VEGF inhibitors have been the cornerstone of their treatment. Anti-VEGF monotherapy is an effective but burdensome treatment for DME. However, due to the intensive and burdensome treatment, most patients in routine clinical practice are undertreated, and therefore, their outcomes are compromised. Even in adequately treated patients, persistent DME is reported anywhere from 30% to 60% depending on the drug used. PDR is currently treated by anti-VEGF, panretinal photocoagulation (PRP) or a combination of both. Similarly, a number of eyes, despite these treatments, continue to progress to tractional retinal detachment and vitreous hemorrhage. Clearly there are other molecular pathways other than VEGF involved in the pathogenesis of DME and PDR. One of these pathways is the angiopoietin–Tie signaling pathway. Angiopoietin 1 (Ang1) plays a major role in maintaining vascular quiescence and stability. It acts as a molecular brake against vascular destabilization and inflammation that is usually promoted by angiopoietin 2 (Ang2). Several pathological conditions including chronic hyperglycemia lead to Ang2 upregulation. Recent regulatory approval of the bi-specific antibody, faricimab, may improve long term outcomes in DME. It targets both the Ang/Tie and VEGF pathways. The YOSEMITE and RHINE were multicenter, double-masked, randomized non-inferiority phase 3 clinical trials that compared faricimab to aflibercept in eyes with center-involved DME. At 12 months of follow-up, faricimab demonstrated non-inferior vision gains, improved anatomic outcomes and a potential for extended dosing when compared to aflibercept. The 2-year results of the YOSEMITE and RHINE trials demonstrated that the anatomic and functional results obtained at the 1 year follow-up were maintained. Short term outcomes of previously treated and treatment-naive eyes with DME that were treated with faricimab during routine clinical practice suggest a beneficial effect of faricimab over other agents. Targeting of Ang2 has been reported by several other means including VE-PTP inhibitors, integrin binding peptide and surrobodies.

Vascular endothelial growth factor in eye disease

Contribution of VEGF and PEDF to Choroidal Angiogenesis: A Need for Balanced Expressions

Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Vascular Endothelial Growth Factor and Diabetic Retinal Disease

Current Status of Vascular Endothelial Growth Factor Inhibition in Age-Related Macular Degeneration

Vascular endothelial growth factor and intraocular neovascularization

[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept]

Progress of Anti-Vascular Endothelial Growth Factor Therapy for Ocular Neovascular Disease: Benefits and Challenges

Anti-VEGF therapy in pediatric retinal and choroidal disease

Indirect blockade of vascular endothelial growth factor: the potential for eye disease therapy

Advances in vascular endothelial growth factor antagonist therapy for ocular neovascularization diseases

Vascular Endothelial Growth Factor C and D Signaling Pathways as Potential Targets for the Treatment of Neovascular Age-Related Macular Degeneration: A Narrative Review

PFKFB3 in neovascular eye disease: unraveling mechanisms and exploring therapeutic strategies

VEGF As a Direct Functional Regulator of Photoreceptors and Contributing Factor to Diabetes-Induced Alteration of Photoreceptor Function

Angiopoietin–Tie Signaling Pathway in Diabetic Retinopathy

Antiangiogenic Therapy for Ocular Diseases: Current Status and Challenges

[The Rational Use of Anti-Vascular Endothelial Growth Factor Drugs to Assist the Treatment of Diabetic Retinopathy].

VEGFR1 signaling in retinal angiogenesis and microinflammation

Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update

Research Progress of VEGFR Small Molecule Inhibitors in Ocular Neovascular Diseases

Clinical Research Progress of Anti-Vegf Agents for Diabetic Retinopathy